Trinidad and Tobago

Resilience System


You are here

COVID-19

The Many Symptoms of Covid-19

For a Texas nurse, the first sign that something was wrong happened while brushing her teeth — she couldn’t taste her toothpaste. For a Georgia attorney, it was hitting a wall of fatigue on a normally easy run. When a Wisconsin professor fell ill in June, he thought a bad meal had upset his stomach.

But eventually, all of these people discovered that their manifold symptoms were all signs of Covid-19. Some of the common symptoms — a dry cough, a headache — can start so mildly they are at first mistaken for allergies or a cold. In other cases, the symptoms are so unusual — strange leg pain, a rash or dizziness — that patients and even their doctors don’t think Covid-19 could be the culprit.

Problem, Solution, SitRep, or ?: 

Trump considering blocking Americans from returning to the U.S. if they’re suspected of having the coronavirus.

 

President Trump is considering new immigration regulations that would allow border officials to temporarily block American citizens and legal permanent residents from returning to the United States from abroad if authorities believe they may be infected with the coronavirus.

In recent months, Mr. Trump has imposed sweeping rules that ban entry by foreigners into the United States, citing the risk of allowing the virus to spread from hot spots abroad. But those rules have exempted two categories of people attempting to return: American citizens and non-citizens who have already established legal residence.

Problem, Solution, SitRep, or ?: 

New study on Asymptomatic People Carrying the Coronavirus in High Amounts

Of all the coronavirus’s qualities, perhaps the most surprising has been that seemingly healthy people can spread it to others. This trait has made the virus difficult to contain, and continues to challenge efforts to identify and isolate infected people.

Problem, Solution, SitRep, or ?: 

Vaccines: Johnson @Johnson and Novavax report contracts, developments

 

NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to COVID-19
howdy folks
Page loaded in 1.331 seconds.